154 related articles for article (PubMed ID: 31401686)
1. Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States.
Pariser AC; Sedghi T; Soulos PR; Killelea B; Gross CP; Mougalian SS
Breast Cancer Res Treat; 2019 Nov; 178(2):419-426. PubMed ID: 31401686
[TBL] [Abstract][Full Text] [Related]
2. How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
Montagna G; Sevilimedu V; Fornier M; Jhaveri K; Morrow M; Pilewskie ML
Ann Surg Oncol; 2020 Nov; 27(12):4702-4710. PubMed ID: 32839900
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes.
Cao L; Sugumar K; Keller E; Li P; Rock L; Simpson A; Freyvogel M; Montero AJ; Shenk R; Miller ME
Ann Surg Oncol; 2021 Oct; 28(10):5730-5741. PubMed ID: 34342757
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
Spring LM; Gupta A; Reynolds KL; Gadd MA; Ellisen LW; Isakoff SJ; Moy B; Bardia A
JAMA Oncol; 2016 Nov; 2(11):1477-1486. PubMed ID: 27367583
[TBL] [Abstract][Full Text] [Related]
5. National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.
Puig CA; Hoskin TL; Day CN; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 May; 24(5):1242-1250. PubMed ID: 28000076
[TBL] [Abstract][Full Text] [Related]
6. The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis.
Wang Y; He L; Song Y; Wu Q; Wang H; Zhang B; Ma X
BMC Womens Health; 2020 Jan; 20(1):17. PubMed ID: 32005117
[TBL] [Abstract][Full Text] [Related]
7. Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study.
Chiba A; Hoskin TL; Heins CN; Hunt KK; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 Feb; 24(2):418-424. PubMed ID: 27663568
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
van de Loo ME; Andour L; van Heesewijk AE; Oosterkamp HM; Liefers GJ; Straver ME
Breast Cancer Res Treat; 2024 May; 205(1):5-16. PubMed ID: 38265568
[TBL] [Abstract][Full Text] [Related]
9. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?
Petruolo O; Sevilimedu V; Montagna G; Le T; Morrow M; Barrio AV
Ann Surg Oncol; 2021 Jan; 28(1):287-294. PubMed ID: 32514804
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review.
Charehbili A; Fontein DB; Kroep JR; Liefers GJ; Mieog JS; Nortier JW; van de Velde CJ
Cancer Treat Rev; 2014 Feb; 40(1):86-92. PubMed ID: 23891267
[TBL] [Abstract][Full Text] [Related]
11. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Barbie TU; Ma C; Margenthaler JA
Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
[TBL] [Abstract][Full Text] [Related]
12. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit.
Spronk PER; Volders JH; van den Tol P; Smorenburg CH; Vrancken Peeters MTFD
Eur J Surg Oncol; 2019 Feb; 45(2):110-117. PubMed ID: 30348601
[TBL] [Abstract][Full Text] [Related]
13. Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men.
Venigalla S; Carmona R; Guttmann DM; Jain V; Freedman GM; Clark AS; Shabason JE
JAMA Oncol; 2018 Oct; 4(10):e181114. PubMed ID: 29800030
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ
Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy use trends among older women with breast cancer: 2010-2017.
Zhang H; Barner JC; Moczygemba LR; Rascati KL; Park C; Kodali D
Breast Cancer Res Treat; 2022 Jun; 193(3):695-705. PubMed ID: 35449473
[TBL] [Abstract][Full Text] [Related]
16. Mortality impact of less-than-standard therapy in older breast cancer patients.
Yood MU; Owusu C; Buist DS; Geiger AM; Field TS; Thwin SS; Lash TL; Prout MN; Wei F; Quinn VP; Frost FJ; Silliman RA
J Am Coll Surg; 2008 Jan; 206(1):66-75. PubMed ID: 18155570
[TBL] [Abstract][Full Text] [Related]
17. Treatment utilization and effectiveness of neoadjuvant chemotherapy comparing men and women diagnosed with breast cancer: a Swedish retrospective cohort study.
Schiza A; Fredriksson I; Sund M; Valachis A
Breast Cancer Res Treat; 2024 Jan; 203(2):235-243. PubMed ID: 37812362
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
[TBL] [Abstract][Full Text] [Related]
19. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States.
Mougalian SS; Soulos PR; Killelea BK; Lannin DR; Abu-Khalaf MM; DiGiovanna MP; Sanft TB; Pusztai L; Gross CP; Chagpar AB
Cancer; 2015 Aug; 121(15):2544-52. PubMed ID: 25902916
[TBL] [Abstract][Full Text] [Related]
20. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]